دورية أكاديمية
أعرض في EDS

Synthesis and biological evaluation of new coumarin derivatives as cytotoxic agents.

التفاصيل البيبلوغرافية
العنوان: Synthesis and biological evaluation of new coumarin derivatives as cytotoxic agents.
المؤلفون: Ragab FA; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt., Eissa AAM; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt., Fahim SH; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt., Salem MA; Pharmaceutical Chemistry Department, Faculty of Pharmacy, October University for Modern Sciences and Arts (MSA), Giza, Egypt.; School of Life and Medical Sciences, University of Hertfordshire hosted by Global Academic Foundation, Cairo, Egypt., Gamal MA; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt., Nissan YM; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.; Pharmaceutical Chemistry Department, Faculty of Pharmacy, October University for Modern Sciences and Arts (MSA), Giza, Egypt.
المصدر: Archiv der Pharmazie [Arch Pharm (Weinheim)] 2021 Aug; Vol. 354 (8), pp. e2100029. Date of Electronic Publication: 2021 Apr 19.
نوع المنشور: Comparative Study; Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley-VCH Verlag GmbH & Co. KGaA Country of Publication: Germany NLM ID: 0330167 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-4184 (Electronic) Linking ISSN: 03656233 NLM ISO Abbreviation: Arch Pharm (Weinheim) Subsets: MEDLINE
أسماء مطبوعة: Publication: <2005->: Weinheim Germany : Wiley-VCH Verlag GmbH & Co. KGaA
Original Publication: Weinheim, Verlag Chemie GmbH.
مواضيع طبية MeSH: Antineoplastic Agents/*pharmacology , Breast Neoplasms/*drug therapy , Coumarins/*pharmacology , Neoplasms/*drug therapy, A549 Cells ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Breast Neoplasms/pathology ; Coumarins/chemical synthesis ; Coumarins/chemistry ; Doxorubicin/pharmacology ; ErbB Receptors/genetics ; Erlotinib Hydrochloride/pharmacology ; HCT116 Cells ; Hep G2 Cells ; Humans ; Inhibitory Concentration 50 ; MCF-7 Cells ; Molecular Docking Simulation ; Neoplasms/genetics ; Neoplasms/pathology ; Solubility ; Structure-Activity Relationship
مستخلص: New coumarin derivatives 9a-f, 10a-e, and 11a-f were synthesized and evaluated for their cytotoxic activity against a human breast cancer cell line (MCF-7). All compounds exhibited good activity in the nanomolar range, using doxorubicin and erlotinib as positive controls. The most active compound 9d with IC 50 of 21 nM was tested against the HCT-116, HepG-2, A549, and SGC-7901 cell lines, with IC 50 values of 0.021, 0.170, 0.028, and 0.11 µM, respectively. Compound 9d was further investigated for its ability to suppress the expression of epidermal growth factor receptor (EGFR). Compound 9d decreased the concentration of EGFR by 87%, using erlotinib as a positive control. A docking study revealed similar or higher scores than for erlotinib and similar binding poses providing interactions with the hinge region of the tyrosine kinase (TK). Besides the effect on expression, this in silico investigation predicts the possibility of direct binding between the new coumarin derivatives and the EGFR TK. Moreover, computational calculation for ADME properties for the most active compounds 9d, 9e, 10c, and 11c revealed the expected high gastrointestinal tract absorption, moderate water solubility with no central nervous system toxicity, and druglikeness.
(© 2021 Deutsche Pharmazeutische Gesellschaft.)
References: D. Sloane , in Cancer Epidemiology (Ed: M. Verma), Humana Press 2009, Vol. 471, pp. 65-83.
E. Zwick , J. Bange , A. Ullrich , Endocr. Relat. Cancer 2001, 8, 161.
T. N. Aung , Z. Qu , R. D. Kortschak , D. L. Adelson , Int. J. Mol. Sci. 2017, 18, 656.
J. Bronikowska , E. Szliszka , D. Jaworska , Z. P. Czuba , W. Krol , Molecules 2012, 17, 6449.
T. Devji , C. Reddy , C. Woo , S. Awale , S. Kadota , D. Carrico-Moniz , Bioorg. Med. Chem. Lett. 2011, 21, 5770.
M. Joao Matos , S. Vazquez-Rodriguez , L. Santana , E. Uriarte , C. Fuentes-Edfuf , Y. Santos , A. Munoz-Crego , M. Joao Matos , S. Vazquez-Rodriguez , L. Santana , E. Uriarte , C. Fuentes-Edfuf , Y. Santos , A. Munoz-Crego , Med. Chem. 2012, 8, 1140.
Y. Shi , C.-H. Zhou , Bioorg. Med. Chem. Lett. 2011, 21, 956.
M. Manjunatha , V. H. Naik , A. D. Kulkarni , S. A. Patil , J. Coord. Chem. 2011, 64, 4264.
M. Watzka , C. Geisen , C. G. Bevans , K. Sittinger , G. Spohn , S. Rost , E. Seifried , C. R. Müller , J. Oldenburg , J. Thromb. Haemost. 2011, 9, 109.
S. Weigt , N. Huebler , R. Strecker , T. Braunbeck , T. H. Broschard , Reprod. Toxicol. 2012, 33, 133.
A. A. H. Kadhum , A. A. Al-Amiery , A. Y. Musa , A. B. Mohamad , Int. J. Mol. Sci. 2011, 12, 5747.
W. Qin , C. Liu , W. Jiang , Y. Xue , G. Wang , S. Liu , BMC Microbiol. 2019, 19, 50.
M.-B. Nayeli , H.-R. Maribel , J.-F. Enrique , B.-P. Rafael , A.-F. Margarita , F.-M. Macrina , M.D. Ivan , G.C. Manasés Nat. Prod. Res. 2020, 34, 3244.
C. Mu , M. Wu , Z. Li , Chem. Biodiversity 2018, 16, e1800559.
N. Lv , M. Sun , C. Liu , J. Li , Bioorg. Med. Chem. Lett. 2017, 27, 4578.
T. Nasr , S. Bondock , M. Youns , Eur. J. Med. Chem. 2014, 76, 539.
N. S. Goud , M. S. Ghouse , J. Vishnu , J. Pranay , R. Alvala , V. Talla , I. A. Qureshi , M. Alvala , Anticancer Agents Med. Chem. 2019, 19, 557.
T. K. Mohamed , R. Z. Batran , S. A. Elseginy , M. M. Ali , A. E. Mahmoud , Bioorg. Chem. 2019, 85, 253.
L. J. Lombardo , F. Y. Lee , P. Chen , D. Norris , J. C. Barrish , K. Behnia , S. Castaneda , L. Cornelius , J. Das , A. M. Doweyko , C. Fairchild , J. T. Hunt , I. Inigo , K. Johnston , A. Kamath , D. Kan , H. Klei , P. Marathe , S. Pang , R. Peterson , S. Pitt , G. L. Schieven , R. J. Schmidt , J. Tokarski , M. L. Wen , J. Wityak , R. M. Borzilleri , J. Med. Chem. 2004, 47, 6658.
Y. Chen , H.-R. Liu , H.-S. Liu , M. Cheng , P. Xia , K. Qian , P. C. Wu , C. Y. Lai , Y. Xia , Z. Y. Yang , S. L. Morris-Natschke , K. H. Lee , Eur. J. Med. Chem. 2012, 49, 74.
X.-Q. Wu , C. Huang , Y.-M. Jia , B.-A. Song , J. Li , X.-H. Liu , Eur. J. Med. Chem. 2014, 74, 717.
D. R. Vianna , L. Hamerski , F. Figueiró , A. Bernardi , L. C. Visentin , E. N. S. Pires , H. F. Teixeira , C. G. Salbego , V. L. Eifler-Lima , A. Battastini , G. L. von Poser , A. C. Pinto , Eur. J. Med. Chem. 2012, 57, 268.
E. Bin Yang , Y. N. Zhao , K. Zhang , P. Mack , Biochem. Biophys. Res. Commun. 1999, 260, 682.
N. S. Reddy , K. Gumireddy , M. R. Mallireddigari , S. C. Cosenza , P. Venkatapuram , S. C. Bell , E. P. Reddy , M. Reddy , Bioorg. Med. Chem. 2005, 13, 3141.
K. N. Venugopala , V. Rashmi , B. Odhav , BioMed Res. Int. 2013, 2013, 1.
K. M. Amin , A. A. M. Eissa , S. M. Abou-Seri , F. M. Awadallah , G. S. Hassan , Eur. J. Med. Chem. 2013, 60, 187.
B. Kahveci , F. Yılmaz , E. Menteşe , S. Ülker , Arch. Pharm. (Weinheim) 2017, 350, 1600369.
R. Z. Batran , D. H. Dawood , S. A. El-Seginy , M. M. Ali , T. J. Maher , K. S. Gugnani , A. N. Rondon-Ortiz , Arch. Pharm. (Weinheim) 2017, 350, 1700064.
K. M. Amin , A. M. Taha , R. F. George , N. M. Mohamed , F. F. Elsenduny , Arch. Pharm. (Weinheim) 2018, 351, 1700199.
E. Menteşe , A. Güner , E. Polatlı , M. Emirik , H. Bektaş , B. Kahveci , Arch. Pharm. (Weinheim) 2020, 354, 2000284.
M. M. Ghorab , M. S. Alsaid , Y. M. Nissan , Life Sci. J. 2013, 10, 2170.
M. M. Ghorab , M. S. Alsaid , M. S. A. El-Gaby , M. M. Elaasser , Y. M. Nissan , Chem. Cent. J. 2017, 11, 32.
M. M. Ghorab , M. S. Alsaid , M. S. Al-Dosary , Y. M. Nissan , S. M. Attia , Chem. Cent. J. 2016, 10, 19.
M. M. Ghorab , M. S. Alsaid , Y. M. Nissan , Acta Pol. Pharm. 2014, 71, 603.
M. M. Ghorab , M. S. Al-Said , Y. M. Nissan , Arzneimittelforschung 2012, 62, 497.
M. M. Ghorab , M. S. Alsaid , M. S. Al-Dosari , Y. M. Nissan , A. A. Al-Mishari , Chem. Cent. J. 2016, 10, 18.
M. M. Ghorab , F. A. Ragab , H. I. Heiba , H. M. Agha , Y. M. Nissan , Arch. Pharm. Res. 2012, 35, 59.
F. W. Canter , F. H. Curd , A. Robertson , J. Chem. Soc. 1931, 0, 1255.
A. Kathuria , N. Priya , K. Chand , P. Singh , A. Gupta , S. Jalal , S. Gupta , H. G. Raj , S. K. Sharma , Bioorg. Med. Chem. 2012, 20, 1624.
E.-M. Kwon , C.-G. Kim , A.-R. Goh , J.-S. Park , J.-G. Jun , Bull. Korean Chem. Soc. 2012, 33, 1939.
N. Kumar , World Res. J. Biochem. 2012, 1, 2279.
E. Bombardelli , P. Valenti , US6767916B2 2004.
K. V. Sashidhara , A. Kumar , M. Kumar , J. Sarkar , S. Sinha , WO/2012/017454 2014.
M. V. Berridge , P. M. Herst , A. S. Tan , Biotechnol. Annu. Rev. 2005, 11, 127.
T. Mosmann , J. Immunol. Methods 1983, 65, 55.
Enzyme-Linked Immunosorbent Assay Kit, www.arp1.com (accessed: July 2017).
N. E. Hynes , H. A. Lane , Nat. Rev. Cancer 2005, 5, 341.
G. M. Morris , R. Huey , W. Lindstrom , M. F. Sanner , R. K. Belew , D. S. Goodsell , A. J. Olson , J. Comput. Chem. 2010, 30, 2785.
E. F. Pettersen , T. D. Goddard , C. C. Huang , G. S. Couch , D. M. Greenblatt , E. C. Meng , T. E. Ferrin , J. Comput. Chem. 2004, 25, 1605.
N. M. O'Boyle , M. Banck , C. A. James , C. Morley , T. Vandermeersch , G. R. Hutchison , J. Cheminf. 2011, 3, 33.
A. Daina , O. Michielin , V. Zoete , Sci. Rep. 2017, 7, 1.
A. Daina , V. Zoete , ChemMedChem 2016, 11, 1117.
C. A. Lipinski , Curr. Drug Discov. 2001, 1, 17.
فهرسة مساهمة: Keywords: EGFR; MCF-7; anticancer activity; coumarin; pyrazoline
المشرفين على المادة: 0 (Antineoplastic Agents)
0 (Coumarins)
80168379AG (Doxorubicin)
DA87705X9K (Erlotinib Hydrochloride)
EC 2.7.10.1 (EGFR protein, human)
EC 2.7.10.1 (ErbB Receptors)
تواريخ الأحداث: Date Created: 20210419 Date Completed: 20211230 Latest Revision: 20211230
رمز التحديث: 20240628
DOI: 10.1002/ardp.202100029
PMID: 33872414
قاعدة البيانات: MEDLINE
الوصف
تدمد:1521-4184
DOI:10.1002/ardp.202100029